Unmasking the Deceptive Nature of Cancer Stem Cells: The Role of CD133 in Revealing Their Secrets

Pospieszna, Julia; Dams-Kozlowska, Hanna; Udomsak, Wachirawit; Murias, Marek; Kucinska, Malgorzata

doi:10.3390/ijms241310910

Cited by 11 publications

(3 citation statements)

References 227 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD133 (also known as prominin-1 and AC133) has been identified as a surface marker of cancer stem cells (CSCs) in an increasing number of investigations and has been detected in various solid tumors, including ovarian cancer [12,13]. Our earlier analysis demonstrated that CD133 is involved in the carcinogenesis of serous ovarian cancer, with dynamically elevated expression in high-grade serous carcinoma entities [14].…”

Section: Cd133 Cd47 and Pd-l1 Expression In Ovarian High-grade Serous...mentioning

confidence: 99%

CD133, CD47, and PD-L1 Expression in Ovarian High-grade Serous Carcinoma and Its Association with Metastatic Disease: A Cross-sectional Study

Masadah,

Ikram,

Riadi

et al. 2024

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Introduction: Ovarian cancer is a primary cause of cancer-related death in women. At the time of diagnosis, the majority of ovarian malignancies had metastasized. It is believed that cancer stem cells (CSCs) and immune evasion play a crucial role in the metastatic process. The objective of this study was to describe the expression profiles of cluster of differentiation (CD)133, CD47 , and programmed death ligand 1 ( PD-L1 ) in high-grade serous ovarian cancer (HGSC) as commonly utilized markers for CSCs and immune evasion. Material and methods: Using an immunohistochemical procedure, 51 HGSC tissue samples were stained with anti- CD133 , anti- CD47 , and anti- PDL1 antibodies. The samples contained 31 HGSC with metastases and 20 HGSC absent metastases. The expression of CD133, CD47 , and PD-L1 was compared between groups. Results: Strong expression of CD133 and CD47 was seen in 52% and 66% of tissue samples, respectively. Twenty of the thirty-one patients with metastases had a significant level of CD133 expression, with a p-value of 0.039. CD47 expression was increased in 26 of 31 samples with metastatic disease. A 62.7 percent of samples were negative for PD-L1 expression, significantly inversely correlated with HGSC metastatic disease (p=0.023). Although there was no significant association between CD133, CD47, or PD-L1 expression and age, Tumor Infiltrating Lymphocytes demonstrated a significantly varied relationship. Conclusion: Our findings suggested that expression of CD133, CD47 , and PD-L1 may have dynamically increased as the primary lesion progressed to the metastatic lesion, implying that these proteins may be involved in the progression of high-grade serous ovarian cancer from the primary to the metastatic stage.

show abstract

Section: Cd133 Cd47 and Pd-l1 Expression In Ovarian High-grade Serous...mentioning

confidence: 99%

CD133, CD47, and PD-L1 Expression in Ovarian High-grade Serous Carcinoma and Its Association with Metastatic Disease: A Cross-sectional Study

Masadah,

Ikram,

Riadi

et al. 2024

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…The role of CD133 in tumor progression is further evidenced by the results of the preclinical and clinical studies of antitumor drugs targeting the CD133 molecule (for more information, see reviews [110,111]). Such approaches include delivery systems for conventional chemotherapy drugs, as well as drugs that activate the cytotoxic mechanisms of the immune system.…”

Section: Cd133 As a Target Of Therapies Aimed To Eliminate The Most M...mentioning

confidence: 99%

Can CD133 Be Regarded as a Prognostic Biomarker in Oncology: Pros and Cons

Gisina,

Kim,

Yarygin

et al. 2023

IJMS

View full text Add to dashboard Cite

The CD133 cell membrane glycoprotein, also termed prominin-1, is expressed on some of the tumor cells of both solid and blood malignancies. The CD133-positive tumor cells were shown to exhibit higher proliferative activity, greater chemo- and radioresistance, and enhanced tumorigenicity compared to their CD133-negative counterparts. For this reason, CD133 is regarded as a potential prognostic biomarker in oncology. The CD133-positive cells are related to the cancer stem cell subpopulation in many types of cancer. Recent studies demonstrated the involvement of CD133 in the regulation of proliferation, autophagy, and apoptosis in cancer cells. There is also evidence of its participation in the epithelial–mesenchymal transition associated with tumor progression. For a number of malignant tumor types, high CD133 expression is associated with poor prognosis, and the prognostic significance of CD133 has been confirmed in a number of meta-analyses. However, some published papers suggest that CD133 has no prognostic significance or even demonstrate a certain correlation between high CD133 levels and a positive prognosis. This review summarizes and discusses the existing evidence for and against the prognostic significance of CD133 in cancer. We also consider possible reasons for conflicting findings from the studies of the clinical significance of CD133.

show abstract

“…The ongoing interest in the CD133 molecule is due to its strong association with the phenotypes of stem and progenitor cells, including cancer stem cells, which are responsible for tumor relapses and metastasis [ 1 , 2 ]. In this regard, CD133 is often considered as a potential prognostic biomarker for various oncological diseases, as well as a promising target for cancer therapy [ 3 , 4 ]. The association of CD133 with cancer progression and poor prognosis was shown in meta-analyses devoted to such malignancies as breast cancer [ 5 ], colorectal cancer [ 6 , 7 , 8 , 9 ], gastric cancer [ 10 , 11 ], glioma [ 12 , 13 , 14 ], head and neck squamous cell carcinoma [ 15 ], hepatocellular carcinoma [ 16 , 17 , 18 ], non-small cell lung cancer [ 19 , 20 , 21 ], osteosarcoma [ 22 ], ovarian cancer [ 23 , 24 ] and pancreatic ductal adenocarcinoma [ 25 ].…”

Section: Introductionmentioning

confidence: 99%

The Impact of Glycosylation on the Functional Activity of CD133 and the Accuracy of Its Immunodetection

Gisina,

Yarygin,

Lupatov

2024

Biology

View full text Add to dashboard Cite

The membrane glycoprotein CD133 (prominin-1) is widely regarded as the main molecular marker of cancer stem cells, which are the most malignant cell subpopulation within the tumor, responsible for tumor growth and metastasis. For this reason, CD133 is considered a promising prognostic biomarker and molecular target for antitumor therapy. Under normal conditions, CD133 is present on the cell membrane in glycosylated form. However, in malignancies, altered glycosylation apparently leads to changes in the functional activity of CD133 and the availability of some of its epitopes for antibodies. This review focuses on CD133’s glycosylation in human cells and its impact on the function of this glycoprotein. The association of CD133 with proliferation, differentiation, apoptosis, autophagy, epithelial–mesenchymal transition, the organization of plasma membrane protrusions and extracellular trafficking is discussed. In this review, particular attention is paid to the influence of CD133’s glycosylation on its immunodetection. A list of commercially available and custom antibodies with their characteristics is provided. The available data indicate that the development of CD133-based biomedical technologies should include an assessment of CD133’s glycosylation in each tumor type.

show abstract

Unmasking the Deceptive Nature of Cancer Stem Cells: The Role of CD133 in Revealing Their Secrets

Cited by 11 publications

References 227 publications

CD133, CD47, and PD-L1 Expression in Ovarian High-grade Serous Carcinoma and Its Association with Metastatic Disease: A Cross-sectional Study

CD133, CD47, and PD-L1 Expression in Ovarian High-grade Serous Carcinoma and Its Association with Metastatic Disease: A Cross-sectional Study

Can CD133 Be Regarded as a Prognostic Biomarker in Oncology: Pros and Cons

The Impact of Glycosylation on the Functional Activity of CD133 and the Accuracy of Its Immunodetection

Contact Info

Product

Resources

About